Total immunotherapy for Hodgkin lymphoma.
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Total immunotherapy for Hodgkin lymphoma.
Author(s) :
Houot, Roch [Auteur]
Université de Rennes [UR]
Merryman, Reid W. [Auteur]
Dana-Farber Cancer Institute [Boston]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Université de Rennes [UR]
Merryman, Reid W. [Auteur]
Dana-Farber Cancer Institute [Boston]
Morschhauser, Franck [Auteur]

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Journal title :
Lancet Haematology
Abbreviated title :
Lancet Haematol.
Volume number :
7
Pages :
e629-e630
Publisher :
Elsevier
Publication date :
2020-08-29
ISSN :
2352-3026
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
The anti-CD30 antibody-drug conjugate brentuximab vedotin and the programmed cell death 1 (PD-1) monoclonal antibodies nivolumab and pembrolizumab have dramatically improved outcomes for patients with relapsed or refractory ...
Show more >The anti-CD30 antibody-drug conjugate brentuximab vedotin and the programmed cell death 1 (PD-1) monoclonal antibodies nivolumab and pembrolizumab have dramatically improved outcomes for patients with relapsed or refractory classic Hodgkin lymphoma. With the goal of improving the depth and duration of remissions with these drugs, combination strategies investigating various combination partners are underway, including conventional chemotherapy and other checkpoint inhibitors. Trials investigating the combination of nivolumab and brentuximab vedotin in first and second-line settings showed a significant improvement in complete response rate compared with treatment with either nivolumab or brentuximab vedotin alone, suggesting the potential of this approach.Show less >
Show more >The anti-CD30 antibody-drug conjugate brentuximab vedotin and the programmed cell death 1 (PD-1) monoclonal antibodies nivolumab and pembrolizumab have dramatically improved outcomes for patients with relapsed or refractory classic Hodgkin lymphoma. With the goal of improving the depth and duration of remissions with these drugs, combination strategies investigating various combination partners are underway, including conventional chemotherapy and other checkpoint inhibitors. Trials investigating the combination of nivolumab and brentuximab vedotin in first and second-line settings showed a significant improvement in complete response rate compared with treatment with either nivolumab or brentuximab vedotin alone, suggesting the potential of this approach.Show less >
Language :
Anglais
Audience :
Internationale
Administrative institution(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Submission date :
2023-05-25T03:28:46Z
2023-09-06T08:43:11Z
2023-09-06T08:43:11Z